- Home
- CNF vs VNRX Comparison
CNF vs VNRX Comparison
Compare CNF & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | VNRX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.5M | 35.0M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNF | VNRX |
|---|---|---|
| Price | $5.64 | $0.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 7.2K | ★ 2.3M |
| Earning Date | 03-26-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,241,013.00 | $1,472,007.00 |
| Revenue This Year | $252.34 | $55.98 |
| Revenue Next Year | N/A | $420.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $2.36 | $0.21 |
| 52 Week High | $12.30 | $0.94 |
Technical Indicators
Market Signals| Indicator | CNF | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 36.45 |
| Support Level | $5.23 | $0.24 |
| Resistance Level | $5.76 | $0.28 |
| Average True Range (ATR) | 0.33 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 63.64 | 7.61 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.